세계의 MSI-H 및 dMMR 시장 보고서(2025년)

MSI-H (microsatellite instability-high) and dMMR (deficient mismatch repair) refer to genetic abnormalities in which the DNA repair system fails to correct replication errors, resulting in high mutation rates. These biomarkers are commonly found in cancers such as colorectal and endometrial cancer. Tumors exhibiting MSI-H and dMMR tend to respond well to immunotherapy due to their high immunogenicity.

The primary treatment types for MSI-H and dMMR include immune checkpoint inhibitors (ICIs) and combination therapies. ICIs are drugs that boost the immune system's ability to fight cancer by blocking proteins such as PD-1, PD-L1, or CTLA-4, which tumors use to evade immune detection. These treatments are used across multiple cancer indications, including endometrial, gastric, colorectal, small intestine, and cervical cancers, among others, and are applicable in both early and advanced cancer stages. They are administered in a range of settings, including hospitals, oncology clinics, research institutions, and homecare environments.

The MSI-H and dMMR market research report is one of a series of new reports from The Business Research Company that provides MSI-H and dMMR market statistics, including MSI-H and dMMR industry global market size, regional shares, competitors with a MSI-H and dMMR market share, detailed MSI-H and dMMR market segments, market trends and opportunities, and any further data you may need to thrive in the MSI-H and dMMR industry. This MSI-H and dMMR market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The MSI-H and dMMR market size has grown exponentially in recent years. It will grow from $6.15 billion in 2024 to $7.59 billion in 2025 at a compound annual growth rate (CAGR) of 23.3%. The growth in the historic period can be attributed to the rising incidence of colorectal and endometrial cancers, the expansion of genetic screening programs, increased clinical adoption of MSI testing, growing awareness of hereditary cancer syndromes, and the rising use of liquid biopsy technologies.

The MSI-H and dMMR market size is expected to see exponential growth in the next few years. It will grow to $17.40 billion in 2029 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to the increasing demand for personalized cancer therapies, expanding applications of next-generation sequencing, rising healthcare expenditure in oncology, the growing number of clinical trials for immune checkpoint inhibitors, and regulatory support for companion diagnostics. Major trends in the forecast period include the integration of artificial intelligence in diagnostic workflows, strategic partnerships between pharmaceutical and diagnostic companies, the development of multiplex biomarker panels, advances in immunotherapy, and a shift toward pan-cancer biomarker testing.

The rising prevalence of cancer is expected to drive the growth of the MSI-H and dMMR market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells. A key factor contributing to its rising incidence is the aging global population, as cancer risk increases with age due to the accumulation of genetic mutations and extended exposure to environmental and lifestyle-related risk factors. MSI-H (microsatellite instability-high) and dMMR (deficient mismatch repair) biomarkers play a critical role in identifying tumors with impaired DNA repair mechanisms and high mutation burdens. These characteristics make tumors more responsive to immune checkpoint inhibitors, thereby guiding personalized immunotherapy decisions and informing prognosis and genetic risk assessments. For instance, in January 2024, the American Cancer Society reported that in 2023, the United States was expected to see 1,958,310 new cancer cases and 609,820 related deaths. These numbers were projected to increase in 2024 to approximately 2,001,140 new cases and 611,720 deaths. This growing cancer burden underscores the need for advanced biomarker-driven therapies, fueling demand for MSI-H and dMMR testing.

Here's a refined version of your paragraph with improved flow, clarity, and professional tone

--

• *Innovative Combination Therapies Transforming MSI-H and dMMR Cancer Treatment**

Major companies operating in the MSI-H and dMMR market are increasingly focused on developing innovative combination therapies to enhance treatment efficacy and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves using two or more treatment modalities-commonly immunotherapy agents such as checkpoint inhibitors-either alone or in conjunction with chemotherapy, targeted therapies, or radiation. This multifaceted approach aims to amplify immune response, overcome resistance mechanisms, and extend survival in patients with tumors characterized by high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, received U.S. Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with MSI-H or dMMR features. This approval represents a significant advancement in the treatment landscape, offering a powerful dual immunotherapy regimen that targets complementary pathways, thereby improving patient response rates and survival while addressing an area of high unmet clinical need.

In December 2023, Owkin Inc., a France-based firm specializing in AI-powered drug discovery and precision medicine, joined forces with Merck & Co. Inc. to develop digital pathology diagnostics for cancer using artificial intelligence. The partnership seeks to improve MSI-H testing rates across several cancer types in the EU, including endometrial, gastric, small intestinal, and biliary cancers. By utilizing AI, the initiative aims to enhance diagnostic precision, optimize lab workflows, and more effectively align patients with suitable treatments. Merck & Co. Inc. is a U.S.-based pharmaceutical company, known for providing KEYTRUDA (pembrolizumab) for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) cancers.

Major players in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in MSI-H and dMMR report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the MSI-H and dMMR market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The MSI-H and dMMR market consists of revenues earned by entities by providing services such as genetic and molecular diagnostic testing, personalized treatment planning, and immunotherapy administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The MSI-H and dMMR market consists of sales of bispecific antibodies, monoclonal antibodies, and oncolytic virus therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

MSI-H And dMMR Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on msi-h and dmmr market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for msi-h and dmmr ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The msi-h and dmmr market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs); Combination Therapy
• 2) By Indication: Endometrial; Gastric; Colorectal Cancer; Small Intestine Cancer; Cervical Cancer; Other Indications
• 3) By Stage: Early Stages; Advanced Stages
• 4) By End User: Hospitals; Oncology Clinics; Research Institutions; Homecare
• Subsegments:
• 1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors; Programmed Cell Death Ligand 1 Inhibitors; Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
• 2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy; Immune Checkpoint Inhibitor + Targeted Therapy; Immune Checkpoint Inhibitor + Radiation Therapy; Immune Checkpoint Inhibitor + Other Immunotherapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. MSI-H And dMMR Market Characteristics

3. MSI-H And dMMR Market Trends And Strategies

4. MSI-H And dMMR Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global MSI-H And dMMR Growth Analysis And Strategic Analysis Framework

• 5.1. Global MSI-H And dMMR PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global MSI-H And dMMR Market Growth Rate Analysis
• 5.4. Global MSI-H And dMMR Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global MSI-H And dMMR Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global MSI-H And dMMR Total Addressable Market (TAM)

6. MSI-H And dMMR Market Segmentation

• 6.1. Global MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors (ICIs)
• Combination Therapy
• 6.2. Global MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endometrial
• Gastric
• Colorectal Cancer
• Small Intestine Cancer
• Cervical Cancer
• Other Indications
• 6.3. Global MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Stages
• Advanced Stages
• 6.4. Global MSI-H And dMMR Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Clinics
• Research Institutions
• Homecare
• 6.5. Global MSI-H And dMMR Market, Sub-Segmentation Of Immune Checkpoint Inhibitors (ICIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Programmed Cell Death Protein 1 Inhibitors
• Programmed Cell Death Ligand 1 Inhibitors
• Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
• 6.6. Global MSI-H And dMMR Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitor + Chemotherapy
• Immune Checkpoint Inhibitor + Targeted Therapy
• Immune Checkpoint Inhibitor + Radiation Therapy
• Immune Checkpoint Inhibitor + Other Immunotherapies

7. MSI-H And dMMR Market Regional And Country Analysis

• 7.1. Global MSI-H And dMMR Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global MSI-H And dMMR Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific MSI-H And dMMR Market

• 8.1. Asia-Pacific MSI-H And dMMR Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China MSI-H And dMMR Market

• 9.1. China MSI-H And dMMR Market Overview
• 9.2. China MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India MSI-H And dMMR Market

• 10.1. India MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan MSI-H And dMMR Market

• 11.1. Japan MSI-H And dMMR Market Overview
• 11.2. Japan MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia MSI-H And dMMR Market

• 12.1. Australia MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia MSI-H And dMMR Market

• 13.1. Indonesia MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea MSI-H And dMMR Market

• 14.1. South Korea MSI-H And dMMR Market Overview
• 14.2. South Korea MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe MSI-H And dMMR Market

• 15.1. Western Europe MSI-H And dMMR Market Overview
• 15.2. Western Europe MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK MSI-H And dMMR Market

• 16.1. UK MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany MSI-H And dMMR Market

• 17.1. Germany MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France MSI-H And dMMR Market

• 18.1. France MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy MSI-H And dMMR Market

• 19.1. Italy MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain MSI-H And dMMR Market

• 20.1. Spain MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe MSI-H And dMMR Market

• 21.1. Eastern Europe MSI-H And dMMR Market Overview
• 21.2. Eastern Europe MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia MSI-H And dMMR Market

• 22.1. Russia MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America MSI-H And dMMR Market

• 23.1. North America MSI-H And dMMR Market Overview
• 23.2. North America MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA MSI-H And dMMR Market

• 24.1. USA MSI-H And dMMR Market Overview
• 24.2. USA MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada MSI-H And dMMR Market

• 25.1. Canada MSI-H And dMMR Market Overview
• 25.2. Canada MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America MSI-H And dMMR Market

• 26.1. South America MSI-H And dMMR Market Overview
• 26.2. South America MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil MSI-H And dMMR Market

• 27.1. Brazil MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East MSI-H And dMMR Market

• 28.1. Middle East MSI-H And dMMR Market Overview
• 28.2. Middle East MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa MSI-H And dMMR Market

• 29.1. Africa MSI-H And dMMR Market Overview
• 29.2. Africa MSI-H And dMMR Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa MSI-H And dMMR Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa MSI-H And dMMR Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. MSI-H And dMMR Market Competitive Landscape And Company Profiles

• 30.1. MSI-H And dMMR Market Competitive Landscape
• 30.2. MSI-H And dMMR Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. MSI-H And dMMR Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. AstraZeneca PLC
• 31.3. Bristol-Myers Squibb Company
• 31.4. GSK plc.
• 31.5. Takeda Pharmaceutical Company
• 31.6. Incyte Corporation
• 31.7. Exact Sciences Corp.
• 31.8. BeiGene LTD.
• 31.9. Summit Therapeutics Inc.
• 31.10. Tempus Labs Inc.
• 31.11. Guardant Health
• 31.12. NeoGenomics Laboratories Inc.
• 31.13. Promega Corporation
• 31.14. Caris Life Sciences
• 31.15. Owkin

32. Global MSI-H And dMMR Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The MSI-H And dMMR Market

34. Recent Developments In The MSI-H And dMMR Market

35. MSI-H And dMMR Market High Potential Countries, Segments and Strategies

• 35.1 MSI-H And dMMR Market In 2029 - Countries Offering Most New Opportunities
• 35.2 MSI-H And dMMR Market In 2029 - Segments Offering Most New Opportunities
• 35.3 MSI-H And dMMR Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer